Ibrutinib-associated Pneumocystis jirovecii pneumonia

Am J Hematol. 2017 Nov;92(11):E646-E648. doi: 10.1002/ajh.24890. Epub 2017 Sep 28.

Authors

Regina Lee¹, Afrouz Nayernama¹, S Christopher Jones¹, Tanya Wroblewski², Peter E Waldron¹

Affiliations

¹ Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
² Division of Hematology Products, Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.

PMID: 28815693
DOI: 10.1002/ajh.24890

No abstract available

Publication types

Letter

MeSH terms

Adenine / analogs & derivatives
Adult
Aged
Aged, 80 and over
Female
Humans
Male
Middle Aged
Piperidines
Pneumocystis carinii*
Pneumonia, Pneumocystis / chemically induced*
Pneumonia, Pneumocystis / drug therapy*
Pneumonia, Pneumocystis / mortality
Pyrazoles / administration & dosage
Pyrazoles / adverse effects*
Pyrimidines / administration & dosage
Pyrimidines / adverse effects*

Substances

Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Adenine